FLT3 and acute myeloid leukemia: Of the 87 older/unfit patients with newly diagnosed FLT3-mutated AML treated at our institution, 60 (69%) and 27 (31%) received doublet (LIC + FLT3 inhibitor) and triplet (LIC + FLT3 inhibitor + Venetoclax) regimens, respectively (Fig. 1).